Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRICOR (MICRONIZED) vs KYNAMRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tricor (micronized fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
Adjunctive therapy to diet for adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb),Adjunctive therapy to diet for adult patients with severe hypertriglyceridemia (Fredrickson types IV and V),Fenofibrate is indicated as an adjunct to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia,Reduction of triglycerides in patients with hypertriglyceridemia (types IV and V hyperlipidemia)
Adjunct to lipid-lowering medications and diet to reduce LDL-C, apo B, total cholesterol, and non-HDL-C in patients with homozygous familial hypercholesterolemia (Ho FH)
Initial 48 mg (1 tablet) orally once daily with meals. May increase to 96 mg (2 tablets) once daily with meals. Maximum dose 96 mg/day.
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
Terminal elimination half-life is approximately 20 hours (range 15-25 hours) in patients with normal renal function. Half-life is prolonged in renal impairment, requiring dose adjustment when e GFR < 30 m L/min/1.73 m².
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
Fenofibrate is a prodrug that is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid. Fenofibric acid is further metabolized by glucuronidation and excreted in urine. Major metabolic pathways involve hepatic glucuronidation via UGT1A1 and UGT1A3, with minor CYP-mediated metabolism (CYP3A4, CYP2C9).
Primarily metabolized by endonucleases and exonucleases. Not a substrate for CYP450 enzymes.
Primarily renal excretion of glucuronide conjugate, accounting for approximately 60-70% of elimination; fecal excretion accounts for about 25%. Minimal unchanged drug in urine.
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Highly protein-bound (>99%), primarily to albumin.
Greater than 90% bound to plasma proteins, predominantly albumin.
Apparent volume of distribution is approximately 0.5 L/kg (range 0.2-0.9 L/kg). This moderate Vd indicates limited extravascular distribution, primarily intravascular and interstitial fluid spaces.
Approximately 9.6 L/kg, indicating extensive tissue distribution (e.g., liver, kidney).
Oral bioavailability is approximately 66% (range 50-90%) after administration of micronized fenofibrate capsules taken with food. Absorption is enhanced by food; bioavailability is reduced when taken on an empty stomach.
Subcutaneous administration: approximately 90% bioavailability; not administered intravenously clinically.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²). For mild to moderate impairment (e GFR 30-80 m L/min/1.73 m²), reduce dose to 48 mg once daily. Not to exceed 48 mg/day.
No dose adjustment is required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis; use with caution.
Contraindicated in active liver disease or unexplained persistent liver function abnormalities. For Child-Pugh class A or B, avoid use due to potential risk; no specific dose adjustment recommendations, but cautious use only if benefit outweighs risk. Contraindicated in Child-Pugh class C.
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Safety and effectiveness in pediatric patients have not been established; use not recommended in children.
Safety and efficacy in pediatric patients have not been established; not recommended for use in patients under 18 years of age.
Select dose cautiously starting at the lower end of dosing range (48 mg once daily) due to possible decreased renal function and increased risk of adverse effects. Monitor renal function and adjust accordingly.
No specific dose adjustments for elderly patients; clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
There is no FDA black box warning for Tricor (micronized fenofibrate).
Risk of hepatotoxicity: Kynamro can cause elevations in serum transaminases and hepatic steatosis. Monitor liver function before and during treatment. Do not use in patients with moderate or severe hepatic impairment.
Hepatotoxicity: elevations of serum transaminases; monitor liver function tests,Cholelithiasis: fenofibrate may increase cholesterol excretion into bile, leading to gallstones,Pancreatitis: risk may be increased, especially in patients with severe hypertriglyceridemia,Myopathy/rhabdomyolysis: risk increased when used with HMG-Co A reductase inhibitors (statins) or other fibrates,Renal impairment: dose adjustment required; contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²)
Hepatotoxicity: monitor ALT, AST, alkaline phosphatase, and total bilirubin before each dose; discontinue if clinically significant toxicity occurs.,Hepatic steatosis: may cause fatty liver; advise patients to report symptoms of liver injury.,Injection site reactions: common and may be severe.,Flu-like symptoms: common; may require symptomatic treatment.,Allergic reactions: including angioedema and urticaria.,Immune system effects: possible development of anti-drug antibodies and platelet count reductions.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease,Active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities,Pre-existing gallbladder disease,Known hypersensitivity to fenofibrate or any component of the formulation,Breastfeeding (due to potential for serious adverse reactions in nursing infants)
Moderate or severe hepatic impairment (Child-Pugh class B or C),Hypersensitivity to mipomersen or any component of the formulation,Active liver disease or unexplained persistent elevations of serum transaminases
Take with food to enhance absorption. Avoid grapefruit juice. Limit alcohol intake. Maintain a low-fat diet as part of triglyceride management.
Avoid high-fat meals before and after injection. Take KYNAMRO at least 2 hours after any food and at least 1 hour before the next meal to minimize gastrointestinal side effects. No specific food-drug interactions known; however, the drug can increase hepatic fat, so a low-fat diet is generally recommended.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal skeletal variations at high doses. Second and third trimesters: Avoid due to potential fetal harm and insufficient data. Use only if benefit outweighs risk.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended during pregnancy unless clearly necessary.
No data on milk concentration or M/P ratio. Not recommended due to potential for adverse effects in nursing infant; alternatives should be considered.
It is unknown if KYNAMRO is excreted in human milk. No M/P ratio available. A risk to the breastfed infant cannot be excluded; decision to discontinue breastfeeding or drug should consider importance of drug to mother.
No established dosing adjustments. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; monitor efficacy and safety. Consider therapy discontinuation.
No pharmacokinetic studies in pregnancy. No specific dose adjustment recommended; use only if potential benefit justifies potential risk. Standard dose: 200 mg subcutaneously once weekly.
Monitor renal function before and during therapy; reduce dose in e GFR 30-59 m L/min; contraindicated in severe renal impairment (e GFR <30 m L/min). May increase serum creatinine and transaminases. Avoid in active liver disease or unexplained persistent transaminase elevation. Risk of myopathy increases when coadministered with statins, especially in renal impairment. Can be used in combination with statins but monitor for muscle symptoms. Dose adjustment not required in mild to moderate hepatic impairment but use with caution.
KYNAMRO (mipomersen) is an antisense oligonucleotide for homozygous familial hypercholesterolemia (Ho FH). It reduces LDL-C by inhibiting apo B-100 synthesis. Monitor for hepatotoxicity; require ALT, AST, alkaline phosphatase, and bilirubin before each dose. Injection site reactions are common; rotate sites. Consider a statin first-line in Ho FH if tolerated; mipomersen is adjunctive. Avoid in patients with significant liver disease or unexplained persistent transaminase elevations. Do not use in pregnancy due to risk of embryofetal toxicity.
Take with food to improve absorption and reduce GI side effects.,Swallow capsules whole; do not crush, chew, or open.,Avoid consuming grapefruit juice as it may increase drug levels.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,May cause gallstones; report right upper abdominal pain, nausea, or vomiting.,Avoid alcohol as it may increase triglyceride levels and liver effects.,This medication is not a substitute for a healthy diet and exercise; continue lifestyle modifications.,Inform your doctor if you have kidney or liver disease, diabetes, or if you are pregnant or breastfeeding.
KYNAMRO is a weekly injection under the skin for homozygous familial hypercholesterolemia.,You must have blood tests to check your liver before each dose.,Common side effects include injection site redness, swelling, pain, or itching; flu-like symptoms; and nausea.,Do not take KYNAMRO if you are pregnant or planning to become pregnant; use effective contraception.,Take KYNAMRO on the same day each week, at least 2 hours after a meal and at least 1 hour before any food or other oral medications.,Store KYNAMRO in the refrigerator; do not freeze. Allow to warm to room temperature for 30 minutes before injecting.,Contact your doctor immediately if you experience yellowing of skin or eyes, dark urine, or severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRICOR (MICRONIZED) vs KYNAMRO, answered by our medical review team.
TRICOR (MICRONIZED) is a Fibrate Antilipemic that works by Tricor (micronized fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.. KYNAMRO is a Antilipemic that works by Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRICOR (MICRONIZED) and KYNAMRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRICOR (MICRONIZED) is: Initial 48 mg (1 tablet) orally once daily with meals. May increase to 96 mg (2 tablets) once daily with meals. Maximum dose 96 mg/day.. The standard adult dose of KYNAMRO is: Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRICOR (MICRONIZED) and KYNAMRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRICOR (MICRONIZED) is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal skeletal variations at high doses. Second and third trimesters: Avoid due to potenti. KYNAMRO is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended durin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.